After two years of retreat, agritech capital appears to be stirring again. According to the AgFunder’s 2026 Global AgriFoodTech Investment Report, global Agrifoodtech funding held at roughly $16.2 billion in 2025, only modestly down on the prior year. However, under this flatline is a telling shift in the farm, food production and biological technologies segments where deals grew by 7% year-on-year, a value of around $9 billion even as overall deal count fell by 12%. PitchBook’s H1 2026 data tells a similar story of selectivity rather than retreat. Most of deals during this period (valued at $2.4 billion) were concentrated in later-stage companies with demonstrable field return on investment (ROI). This suggests that investors have not entirely walked away from agriculture but have become far more exacting about what they will fund. The biological crop input segment is one of the areas where that exactness is most visible, and the deal calendar has been busiest at both ends of the size spectrum.
Among the major players, BASF completed its acquisition of biological insecticide specialist AgBiTech from Paine Schwartz Partners to strengthen its position in the “fast-growing” segment. Syngenta also struck a strategic partnership with Groundwork BioAg to commercialize mycorrhizal technology, layered on its 2024 acquisition of Intrinsyx Bio and integration of Novartis’s natural-compound strain library. FMC signed a definitive agreement to divest its India commercial crop protection business to Crystal Crop Protection for US$252 million, reshaping its go-to-market footprint.
The same logic is playing out further down the size ladder, among emerging biological platform builders. In March 2026, Frontera Ag, a global biological agriculture platform, signed a definitive agreement to acquire PlantSustain, a plant- and soil-health technology company, from venture builder Generation Food Rural Partners, folding its crop-resilience pipeline into Frontera’s formulation, delivery and regulatory infrastructure.
Across both size tiers, every transaction is a bet that a specific technology, dossier, or market position will perform agronomically, regulatorily, and commercially well beyond the signing date. Therefore, these bets must be backed by substantial evidence and rigorous technical due diligence to avoid costly post-deal surprises.
Why the Diligence Bar is Rising
Technical due diligence, not just financial or legal due diligence, is a crucial gating step for various reasons:
- Capital discipline: With H1 2026 deal counts down roughly 40% year-on-year even as dollars hold up, Agtech acquirers are concentrating fewer, larger checks on assets they can underwrite with evidence, not projections. For those in the biological crop input market, that requires evidence such as trial data, regulatory dossiers, adoption signals, and not only pitch-deck projections.
- Regulatory complexity: Biologicals move across borders under divergent, fast-changing registration frameworks, so a technology registered in Brazil, for example, isn’t automatically registrable, or agronomically transferable, to the EU, sub-Saharan Africa or Southeast Asia. Due diligence involving a jurisdiction-by-jurisdiction regulatory pathway review is key.
- Sustainability as a commercial filter: Retailer sustainability standards, carbon impact, and grower demand for regenerative-practice compatibility now directly shape which products get channel support and are taken up. Ignoring eco-system and carbon impact assessment of target portfolio can lead to mispricing both risk and upside.
Classic financial and legal due diligence alone are necessary but no longer sufficient. It is equally important to assess whether the product works across the target geographies and cropping systems, if the regulatory pathways are realistic on the deal’s timeline, and whether the sustainability profile of interested technology portfolio hold up to relevant scrutiny standards.
Smaller Deals, Bigger Relative Risk
It is tempting to assume diligence rigor should scale with deal size, e. g. that a $250 million divestiture warrants more scrutiny than a platform bolt-on with undisclosed terms. In practice, the opposite often holds. When a biological platform builder acquires an earlier-stage innovator, key risk factors are typically more acute than in a major-to-major deal:
- Thinner data packages: Fewer trial seasons and geographies mean performance is extrapolated from a smaller evidence base. A product that looks strong across two seasons in one region may behave very differently under different soil types, pest pressure or climate of another region.
- Less mature regulatory files: University-licensed or venture-built IP often arrives with partial dossiers, so the acquirer inherits data-gap and timeline risk a major acquirer would already have resolved in-house. University-licensed or venture-built IP often arrives with partial dossiers, with efficacy data generated for research purposes rather than registration, or commercialization and gaps in toxicology or environmental-fate studies. The acquirer inherits data-gap and timeline risk often without realizing how much additional data generation and lead time stands between signing and a sellable, labelled product.
- Concentrated keyperson and channel risk: Value often rides on a handful of founders, a single research collaboration, or one or two early distributor relationships. Unlike a major’s diversified commercial infrastructure, losing a key scientist, a university licensing relationship, or a pilot-market distributor can materially impair the very asset being acquired. These risks are easy to overlook when diligence focuses only on the technology itself.
- No internal diligence bench: A major acquirer such as BASF or Syngenta can lean on in-house regulatory affairs, agronomic and data-science teams to stress-test a target before committing capital. However, a smaller platform acquirer or venture-backed buyer typically has none of this internal capacity, which makes outsourced technical due diligence not a supplementary check but the only credible way to validate the target at all.
- Confidentiality pressure: Smaller deals are frequently sourced through tight, relationship-driven networks such as university tech-transfer offices, regional distributors, or boutique venture builders, where a leak of interest or intent carries outsized reputational and competitive cost. An independent third party that can investigate the target, and quietly test grower or influencer opinion, without revealing the acquirer’s identity is disproportionately valuable in exactly this setting.
Smaller acquisitions carry the same categories of technical and regulatory risk as large strategic deals but with less internal capacity to detect them, less negotiating leverage to price them in, and less room to absorb a costly surprise post-close. That combination is why independent due diligence is particularly critical for deals that look “too small to need it.”
What Dealmakers Need to Validate
A rigorous technical due diligence process applied to biologicals target, typically spans key interconnected workstreams such as:
- Portfolio review: An independent assessment of agronomic performance, competitive positioning and market fit to distinguish genuine differentiation from marketing claims. This means independently interrogating the trial data behind headline performance claims, benchmarking the product against true competitive alternatives rather than the seller’s chosen comparators and identifying where the pipeline has real white space versus where it duplicates what growers can already buy. The output should tell an acquirer not just whether a product works, but whether it wins.
- Regulatory de-risking: Jurisdiction-specific review of registration status, dossier completeness and realistic timelines to approval. This involves auditing the underlying studies against each target market’s current data requirements, flagging any gaps before they become costly surprises. This will also include stress-testing the seller’s stated launch timeline against how long comparable dossiers have taken to clear similar regulatory authorities.
- Sustainability and eco-system assessment: Evaluation of carbon, soil health, water and residue impacts against the frameworks driving sourcing and adoption decisions. This assessment will test whether a target’s sustainability claims are substantiated by data or primarily marketing led.
- Market and influencer validation: The involves confidential engagement with producers, distributors and key opinion leaders to test real-world adoption potential. Technically sound products can still fail commercially if growers don’t trust them, if channel partners are lukewarm, or if the influencers who shape purchasing decisions haven’t been won over. Independent, anonymized outreach conducted without revealing the acquirer’s identity will likely reveal adoption risks in a way that a target’s own customer references, curated by the seller, rarely can.
Evidence is Becoming the Dealmaker
As agritech investment reawakens, it is doing so with more discipline than the last cycle. This discipline applies as much to a platform builder acquiring a start-up as to a major buying a scaled biologicals business. Acquirers of every size are no longer buying growth stories but validated science, defensible regulatory pathways and demonstrable market pull.
Technical due diligence, grounded in independently validated field data, has therefore become critical to transaction outcomes. A missed regulatory data gap can delay a projected launch by a full season or more, while overstated performance or sustainability claims can undermine grower trust and channel support long after a deal closes.
In a market with far less tolerance for surprises, engaging technical expertise early will be the defining discipline of the next investment cycle. Acquirers that integrate technical due diligence into deal sourcing and structuring will be best positioned to turn renewed agritech capital into portfolios that perform.
How AgriThority® Can Help
The team of AgriThority® experts combine strategic and scientific analysis to independently validate agricultural technologies and reduce technical risk. Through StatWerx™, we rapidly analyze and benchmark performance data. TrialWerx® delivers on farm evaluation under commercial scale conditions, while AgriSparx™ provides rigorous, multi-location validation of biological crop inputs, covering agronomic, environmental and economic performance. We also support dossier review, data gap analysis and jurisdiction by jurisdiction regulatory pathway assessment, giving acquirers stronger evidence for confident investment decisions.
